$270 MILLION Medi-Cal Fraud—Unbelievable System Loophole

A 66-year-old Orange County man orchestrated a scheme so brazen it bilked California’s Medicaid program for nearly $270 million in just eleven months, exploiting a temporary gap in oversight that should never have existed.

Quick Take

Paul Richard Randall pleaded guilty to submitting $269 million in fraudulent medication claims to Medi-Cal between May 2022 and April 2023, resulting in $178.7 million in false reimbursements
The scheme exploited Medi-Cal’s suspension of prior authorization requirements during a transition to a new payment system, removing a critical fraud prevention safeguard
Randall operated as a repeat offender, committing this crime while already on release in another criminal case, demonstrating a pattern of systematic exploitation
Federal authorities seized $126.5 million in assets including $111 million in bank funds, nine luxury properties, nine vehicles, and over $1 million in sports memorabilia
The case represents the Trump administration’s aggressive enforcement agenda through its Task Force to Eliminate Fraud, signaling heightened prosecution of healthcare fraud schemes

How a Temporary Fix Became a Fraudster’s Open Door

Medi-Cal’s decision to suspend prior authorization requirements in early 2022 was intended as an administrative streamline. Prior authorization serves as a standard protective mechanism requiring healthcare providers to obtain approval before dispensing certain medications. When Medi-Cal suspended this requirement during its transition to a new payment system, administrators believed the temporary gap posed minimal risk. They were catastrophically wrong. Randall identified this vulnerability immediately and built an entire criminal enterprise around it.

The Anatomy of a $178 Million Theft

Operating through Monte Vista Pharmacy in Garden Grove, Randall orchestrated a sophisticated operation that billed Medi-Cal for medications either medically unnecessary or never dispensed to patients. The scheme involved billing for non-contracted generic drugs manufactured in unique dosages and combinations specifically excluded from Medi-Cal’s maximum price lists. One meloxicam prescription, typically costing five to twenty-five dollars, was billed at thirteen thousand four hundred twenty-four dollars. Over-the-counter vitamin tablets and pain creams received similar astronomical markups. Nurse practitioner Patricia Anderson signed pre-filled prescriptions without meeting patients, reviewing medical records, or determining medical necessity, facilitating the fraud’s operational efficiency.

Randall received approximately forty percent of Monte Vista Pharmacy’s profits from the fraudulent claims, netting him millions while taxpayers and legitimate Medi-Cal beneficiaries bore the cost. The scheme operated with clockwork precision, billing tens of millions monthly until federal investigators finally intervened. From May 2022 through July 2023, the pharmacy submitted more than two hundred sixty-nine million dollars in fraudulent claims before authorities shut down the operation.

A Repeat Offender’s Pattern of Exploitation

What distinguishes this case from typical healthcare fraud is Randall’s status as a repeat offender. He committed this massive scheme while already on release in another criminal case, demonstrating a disturbing pattern of systematic exploitation and law enforcement evasion. This wasn’t a momentary lapse in judgment by an otherwise law-abiding citizen. This was calculated, premeditated criminal enterprise by someone with demonstrated disregard for legal consequences. Federal prosecutors emphasized that his conduct was carefully planned over years specifically to mask evidence of theft.

Randall’s kickback network extended beyond pharmacy operations to patient marketers who supplied beneficiary information in exchange for illegal payments and to healthcare providers who authorized prescriptions without legitimate medical review. This created a criminal ecosystem dependent entirely on Randall’s financial distribution, revealing the depth of his organizational control and the scheme’s systemic nature.

Federal Response and Asset Recovery

On April 7, 2026, Randall pleaded guilty to one count of wire fraud committed while on release. This guilty plea followed earlier guilty pleas by co-conspirators Kyrollos Mekail, the pharmacy owner, in August 2024, and nurse practitioner Patricia Anderson in April 2025. Federal authorities announced the prosecution as part of President Trump’s Task Force to Eliminate Fraud, signaling aggressive enforcement priorities against healthcare fraud schemes.

First Assistant U.S. Attorney Bill Essayli characterized Randall’s actions bluntly: “This defendant used a public health program as his personal piggy bank.” The Justice Department seized approximately one hundred twenty-six point five million dollars in assets, including one hundred eleven million in bank funds and securities, nine luxury vehicles valued at approximately one million dollars, nine luxury real properties worth thirteen point five million dollars, and over one million dollars in sports memorabilia. This represents partial recovery of stolen funds but leaves significant taxpayer losses unrecovered.

An Orange County man has pleaded guilty to a scheme in which he submitted nearly $270 million in fraudulent claims to Medi-Cal, according to the Department of Justice. https://t.co/PooIV9DUzN pic.twitter.com/vPLsUOHaHb

— KTLA (@KTLA) April 8, 2026

Assistant Attorney General A. Tysen Duva emphasized the Criminal Division’s commitment to aggressive prosecution: “He and his co-schemers stole over $178 million through false and fraudulent claims for these medications, lining their own pockets with public funds. The Criminal Division will aggressively prosecute those who defraud Medicaid and exploit taxpayer-funded benefit programs.” Randall faces a maximum thirty-year prison sentence at his scheduled August 3, 2026 sentencing hearing.

Systemic Vulnerabilities and Future Safeguards

This case exposes critical vulnerabilities in healthcare program administration. When government agencies implement temporary policy suspensions during system transitions, they must maintain alternative fraud prevention mechanisms. Medi-Cal’s decision to eliminate prior authorization without establishing compensatory controls created an environment where sophisticated fraudsters could operate with near-impunity for months. Future healthcare program transitions will likely include mandatory enhanced fraud prevention measures during suspension periods, establishing redundant safeguards rather than relying on temporary gaps.

The scheme’s success also reveals how non-contracted drug billing can exploit maximum price list limitations. Fraudsters deliberately billed for unique drug combinations and dosages specifically excluded from price controls, making these medications appear legitimate while enabling dramatic markup. Healthcare programs nationwide will likely implement enhanced monitoring of non-contracted generic drug claims, establishing price reasonableness reviews and beneficiary verification requirements.